Roche reports inadvertent disclosure in lung cancer immunotherapy study

Swiss drug maker Roche said on Wednesday it had been made aware of an inadvertent disclosure in a study of its new immunotherapy for patients with lung cancer using an experimental class of drugs known as anti-TIGIT. The disclosure regards the second interim analysis of Phase III in the Skyscraper 1 study. This evaluated a combination of tiragolumab and Roche's established Tecentriq drug versus Tecentriq alone, a company statement said.